China Pharma Univ. JAK3 compound X15

China Pharma Univ. JAK3 compound X15: sourced facts only. name: "In this study, we describe the discovery of compound X15, a novel JAK3 inhibitor with potent JAK3 inhibitory activity (IC50 = 14.56 nM) and an acceptable pharmacokinetic profile (F = 27.38 %, T1/2 = 20.33 h)." [PMID:40216205]; target: "In this study, we describe the discovery of compound X15, a novel JAK3 inhibitor with potent JAK3 inhibitory activity (IC50 = 14.56 nM) and an acceptable pharmacokinetic profile (F = 27.38 %, T1/2 = 20.33 h)." [PMID:40216205]; developer: "Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 21009, China." [PMID:40216205]; stage: "Furthermore, compound X15 alleviated the symptoms of dermatitis in a DNCB-induced atopic dermatitis Balb/c mice model, with reduced ear thickness at a high dose (90 mg/kg, 0.038 mm) compared to the model group (0.106 mm)." [PMID:40216205]